SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently the focus of intense market conversation as investors keenly await its impending earnings report, with community sentiment weighing high expectations for continued AI-driven growth against concerns of a 'priced to perfection' valuation and significant options volatility.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as Warner Bros. Discovery considers a higher bid from Paramount Skydance, putting pressure on Netflix to either counter or exit the contentious acquisition. Shareholders are actively debating if walking away to secure a substantial breakup fee is the better strategic move, freeing the company from potential debt and regulatory hurdles.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending following recent partnerships with VAST Data and EHC Investment for advanced AI data center solutions, and ahead of anticipated NVIDIA earnings that could further boost the AI infrastructure sector. The community is actively discussing the stock's undervaluation, anticipating a potential short squeeze, and largely dismissing bearish analyst calls amidst perceived market manipulation.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is seeing a significant surge following robust Q4 earnings, which highlighted strong growth in USDC adoption and transaction volumes. This positive report is triggering a notable short squeeze and widespread bullish sentiment, though some investors are cautioning about potential profit-taking and expressing concerns regarding its valuation.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending following FDA Breakthrough Therapy Designation for its Friedreich's ataxia treatment, nomlabofusp, which showed compelling efficacy in clinical trials and is now on a path towards accelerated approval. The community is debating the drug's strong outcomes against manageable safety concerns, while analysts are boosting price targets, signaling significant long-term potential for this rare disease therapy.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending following a notable stock decline, igniting community debate around whether AI advancements, like Anthropic's recent acquisition, represent a competitive threat or validate its strategic position as an AI orchestration platform, with many investors anticipating a rebound driven by strong fundamentals and upcoming earnings.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending due to robust earnings that surpassed expectations, paired with an upbeat FY26 outlook for same-store sales and new restaurant expansion, fueling strong bullish sentiment. The community is actively discussing its premium valuation and growth potential, with bulls comparing it favorably to competitors like Chipotle, while bears highlight persistent margin pressures and a high P/E ratio.

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Eton Pharmaceuticals Inc

Eton Pharmaceuticals is trending following its FDA approval for DESMODA (desmopressin acetate) Oral Solution, a key rare disease treatment. While some investors celebrated a "huge move," others are debating if the news was "priced in," noting a mixed initial price reaction and high short interest amidst a stock halt.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending following a $175 million stock dilution at $15.12 per share, intended to fund the integration of Lanteris Space Systems and advance its 'Solar System Internet' initiatives. While some investors are concerned about the dilution and its immediate impact, many in the community view the resulting share price drop as an overreaction and a buying opportunity, emphasizing the strategic capital raise for future multi-billion dollar NASA contracts and a potential Lunar Terrain Vehicle (LTV) award.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending after a post-earnings sell-off driven by cautious future subscription revenue guidance, despite beating current EPS and revenue estimates. The community is actively debating if the software stock is undervalued following its strong intraday reversal, with many highlighting its AI strategy and the return of its co-founder.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Larimar Therapeutics Sees Unusually High Options Volume (NASDAQ:LRMR)

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) was the target of some unusual options trading on Wednesday. Traders acquired 3,744 call options on the company. This represents an increase...

Larimar Therapeutics' (LRMR) Outperform Rating Reaffirmed at Wedbush

Wedbush reaffirmed an "outperform" rating and issued a $11.00 price objective on shares of Larimar Therapeutics in a research note on Wednesday...

Lifesci Capital Upgrades Larimar Therapeutics (NASDAQ:LRMR) to "Strong-Buy"

Lifesci Capital upgraded Larimar Therapeutics to a "strong-buy" rating in a research note on Tuesday...

Top Penny Stocks To Add to Your Watchlist - February 24th

Larimar Therapeutics, Iovance Biotherapeutics, and Mana Capital Acquisition are the three Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced...

Best Biotech Stocks To Research - February 24th

ImmunityBio, Vir Biotechnology, Larimar Therapeutics, Iovance Biotherapeutics, Danaher, Moderna, and argenex are the seven Biotech stocks to watch today, according to MarketBeat's stock screener...

Tuesday Sector Leaders: Biotechnology, Semiconductors

In trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 2.8%. Leading the group were shares of Larimar Therapeutics, up about 33.7% and shares of Iovance...

<ul class="summary-bullets"><li>The therapy is to treat adults and children with Friedreich’s ataxia, a progressive neurodegenerative disorder.</li><li>Preliminary findings from the open-label study show that nomlabofusp increased FXN levels in patients’ skin to amounts observed in asymptomatic carriers.&nbsp;</li><li>FDA agreed that skin FXN could serve as a novel surrogate endpoint, supporting the planned Biologics License Application submission.</li></ul>Larimar Therapeutics, Inc. (LRMR) announced on Tuesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its frataxin (FXN) protein replacement therapy, nomlabofusp.&nbsp;The therapy is to treat adults and children with Friedreich’s ataxia (FA), a progressive neurodegenerative disorder causing nervous system damage.<h2 class="st-heading-2">FDA Endorses Skin FXN As Surrogate Endpoint</h2>The FDA’s decision follows encouraging clinical data from Larimar’s ongoing open-label study and a recent Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program meeting.&nbsp;The agency also agreed that skin FXN could serve as a novel surrogate endpoint reasonably likely to predict clinical benefit, supporting the planned Biologics License Application (BLA) submission targeted for June 2026. The FDA additionally confirmed that the planned analyses, reference population, and clinical endpoints are aligned with BLA requirements.Following the FDA’s decision,&nbsp;<a href="https://stocktwits.com/symbol/LRMR">Larimar stock</a> traded over 30% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_24_084542_png_18caaedccf.webp" alt="LRMR’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits" width="932" height="105"><figcaption>LRMR’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Feb. 24, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Encouraging Clinical Data</h2>Preliminary findings from the open-label study show that nomlabofusp increased FXN levels in patients’ skin to amounts observed in asymptomatic carriers.&nbsp;Improvements were seen across four key clinical measures, the modified Friedreich Ataxia Rating Scale (mFARS), FARS-Activities of Daily Living (ADL), 9-Hole Peg Test (9-HPT), and Modified Fatigue Impact Scale (MFIS) after one year of treatment.&nbsp;The results suggest that nomlabofusp could slow or reverse FA progression compared with the natural disease course observed in the Friedrich’s Ataxia Clinical Outcomes Measure Study (FACOMS).LRMR stock declined by over 7% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intuit-stock-rallies-pre-market-today-anthropic-connection/cZRvyjtR4C7">Intuit Stock Rallies Pre-Market Today And There’s An Anthropic Connection</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? 

The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.

Equity

The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp.


Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have received an average rating of "Moderate Buy" from the nine analysts that are covering the firm, MarketBeat.com reports. One...

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten ratings firms that are covering the firm, Marketbeat.com reports...

Larimar Therapeutics (NASDAQ:LRMR) Raised to "Strong-Buy" at Leerink Partnrs

Leerink Partnrs raised Larimar Therapeutics to a "strong-buy" rating in a research note on Monday...

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Stocktwits

Stocktwits Polls

The FDA granted Breakthrough Therapy Designation for nomlabofusp, sparking excitement for accelerated development and potential approval for Friedreich's ataxia.

Analysts like Citigroup have raised price targets to $14, with many traders speculating on a sustained run towards $20+.

Elevated short interest, reported around 16-21% of the float, is fueling expectations for a short squeeze amidst rapid price appreciation and high volume.

Concerns about a potential public offering or dilution are a recurring theme, with some traders warning it could temper the stock's current momentum.

Traders are actively engaged, noting its sustained price strength and high volume as it breaks key resistance levels throughout the trading day.

LRMR
Larimar Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LRMR News

LRMRLarimar Therapeutics Inc